title: Voriconazole inhibition of vitamin A metabolism: are adverse events increased in cystic fibrosis patients?
abstract: BACKGROUND
  As Voriconazole is being used more frequently in cystic fibrosis (CF) patients, we aimed to describe the adverse events associated with voriconazole treatment in this population.
  
  
  METHODS
  We performed a retrospective cohort study of all children with CF who received voriconazole between September 2006 and August 2008.
  
  
  RESULTS
  Five of six CF patients receiving treatment developed photosensitivity, whereas all six patients reported visual disturbances. We report two clinical cases of particular interest: a 7-year-old boy developed striking erythema in the face and upper thorax; a 16-year-old girl who reported unexpected visual disturbances, including scotomas and tunneling vision.
  
  
  CONCLUSIONS
  Significant adverse effects of voriconazole were noted in all treated CF patients. We speculate that this may be due to suppression of activity of hepatic enzymes involved in all transretinonic acid metabolism coupled with vitamin A supplementation in CF. Consideration should be given to reducing vitamin A supplementation during voriconazole treatment.
authors.affiliation: Department of Pediatrics, The Montreal Children's Hospital, McGill University, Montreal, Canada.
authors.forename: Matthew Pellan
authors.initials: MP
authors.lastname: Cheng
authors.forename: Katryn
authors.initials: K
authors.lastname: Paquette
authors.forename: Larry C
authors.initials: LC
authors.lastname: Lands
authors.forename: Philippe
authors.initials: P
authors.lastname: Ovetchkine
authors.forename: Yves
authors.initials: Y
authors.lastname: Théoret
authors.forename: Caroline
authors.initials: C
authors.lastname: Quach
mesh_terms: D000293:Adolescent; D000935:Antifungal Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D015331:Cohort Studies; D003550:Cystic Fibrosis / Q000188:drug therapy*; D019587:Dietary Supplements; D005260:Female; D006801:Humans; D008297:Male; D010787:Photosensitivity Disorders / Q000139:chemically induced* / Q000175:diagnosis; D055732:Pulmonary Aspergillosis / Q000188:drug therapy; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use; D012189:Retrospective Studies; D016896:Treatment Outcome; D014230:Triazoles / Q000009:adverse effects* / Q000627:therapeutic use; D014786:Vision Disorders / Q000139:chemically induced* / Q000175:diagnosis; D014801:Vitamin A / Q000378:metabolism*; D065819:Voriconazole
chemical_list: D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D014801:Vitamin A; D065819:Voriconazole